Vaxin Inc. today announced that it has added key patents to its expanding Intellectual Property (IP) portfolio. The clinical stage vaccine and immunotherapeutics company confirmed that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for two patents that protect important elements of its Densigen platform technology for immunotherapeutic treatment of Hepatitis B virus infection, and its RespirVec non-invasive adenoviral vector influenza vaccine. The patents include U.S. Application Serial No. 13/977,265 (the ‘265 application) entitled “Fluorocarbon-Linked Peptide Formulation”, and U.S. Application Serial No. 13/426,037 (the ‘037 application) entitled “Rapid and Prolonged Immunologic-Therapeutic”.
A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. Vaxin now has 37 patents protecting its products in 13 countries.